Syndax Pharmaceuticals, Inc. (SNDX) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1161327,
    "name": "Syndax Pharmaceuticals, Inc.",
    "stock_name": "Syndax Pharmaceuticals, Inc.",
    "full_name": "Syndax Pharmaceuticals, Inc.",
    "name_url": "stocks-analysis/syndax-pharmaceuticals-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "19.74",
    "chg": 0.95,
    "chgp": "5.06%",
    "dir": 1,
    "prev_price": "18.79",
    "mcapval": "1,406.70",
    "mcap": "Small Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2320,
    "indexname": "S&P 500",
    "isin": "US87164F1057",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "2.98 M",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/syndax-pharmaceuticals-inc-1161327-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Syndax Pharmaceuticals Hits Day Low at $13.03 Amid Price Pressure",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/syndax-pharmaceuticals-hits-day-low-at-1303-amid-price-pressure-3649338",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/SyndaxPharmaceu_priceRelatedfactors_3649338.png",
        "date": "2025-10-27 17:39:19",
        "description": "Syndax Pharmaceuticals, Inc. faced a notable decline in stock performance, reflecting ongoing challenges and negative results over 11 consecutive quarters. The company's one-year performance shows a significant drop, contrasting with broader market gains. Despite slight promoter confidence, Syndax's market position remains precarious within the pharmaceuticals sector."
      },
      {
        "title": "Syndax Pharmaceuticals Experiences Revision in Stock Evaluation Amid Market Dynamics",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/syndax-pharmaceuticals-technical-trend-shifts-from-bullish-to-mildly-bullish-amid-stock-price-decline-3649007",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/SyndaxPharmaceu_technicaldot_3649007.png",
        "date": "2025-10-27 15:44:23",
        "description": "Syndax Pharmaceuticals, Inc. has experienced significant stock fluctuations, currently priced at $13.53, down from a 52-week high of $22.50. The company has underperformed compared to the S&P 500 over the past year and three years, indicating ongoing challenges in the biotechnology sector."
      },
      {
        "title": "Syndax Pharmaceuticals Experiences Evaluation Revision Amid Mixed Market Signals and Performance Trends",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/syndax-pharmaceuticals-technical-trend-shifts-from-mildly-bullish-to-bullish-amid-stock-volatility-3617369",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/SyndaxPharmaceu_technicaldot_3617369.png",
        "date": "2025-10-13 15:36:26",
        "description": "Syndax Pharmaceuticals, Inc. has recently revised its evaluation amid market dynamics, with its stock priced at $16.06. The company has shown significant volatility over the past year, with a 52-week high of $22.50 and a low of $8.58, while demonstrating notable year-to-date returns compared to the S&P 500."
      },
      {
        "title": "Is Syndax Pharmaceuticals, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-syndax-pharmaceuticals-inc-technically-bullish-or-bearish-3547208",
        "imagepath": "",
        "date": "2025-09-20 19:49:42",
        "description": "As of 8 September 2025, the technical trend for Syndax Pharmaceuticals, Inc. has changed from mildly bullish to mildly bearish. The weekly MACD and KST are bullish, while the monthly MACD and KST are bearish, indicating mixed signals across different time frames. The daily moving averages are bullish, but the Bollinger Bands and Dow Theory suggest a bearish stance on the monthly level. The stock has underperformed against the S&P 500 over the past week and month, with returns of -5.62% and -2.65% compared to the S&P's gains of 1.05% and 2.33%, respectively. Overall, the current technical stance is mildly bearish, reflecting weakness in the longer-term indicators...."
      },
      {
        "title": "Is Syndax Pharmaceuticals, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-syndax-pharmaceuticals-inc-overvalued-or-undervalued-3543633",
        "imagepath": "",
        "date": "2025-09-20 18:24:30",
        "description": "As of 1 August 2024, the valuation grade for Syndax Pharmaceuticals, Inc. has moved from does not qualify to risky, indicating a shift towards a more cautious outlook. The company appears to be overvalued given its high Price to Book Value of 4.58 and negative EV to EBIT and EV to EBITDA ratios of -2.38, which suggest significant operational challenges. Additionally, the Return on Capital Employed (ROCE) and Return on Equity (ROE) are alarmingly low at -730.60% and -154.01%, respectively, further underscoring the company's financial difficulties.\n\nIn comparison to its peers, Syndax's P/E ratio is not applicable due to its loss-making status, while Protagonist Therapeutics, Inc. is considered very expensive with a P/E of 67.1750, and Aurinia Pharmaceuticals, Inc. is fairly valued with a P/E of 20.8727. The stock has underperformed against the S&P 500 across multiple periods, with a 1-year return of -14.17% c..."
      }
    ],
    "total": 10,
    "sid": "1161327",
    "stock_news_url": "https://www.marketsmojo.com/news/syndax-pharmaceuticals-inc-1161327"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Syndax Pharmaceuticals Hits Day Low at $13.03 Amid Price Pressure

2025-10-27 17:39:19

Syndax Pharmaceuticals, Inc. faced a notable decline in stock performance, reflecting ongoing challenges and negative results over 11 consecutive quarters. The company's one-year performance shows a significant drop, contrasting with broader market gains. Despite slight promoter confidence, Syndax's market position remains precarious within the pharmaceuticals sector.

Syndax Pharmaceuticals Experiences Revision in Stock Evaluation Amid Market Dynamics

2025-10-27 15:44:23

Syndax Pharmaceuticals, Inc. has experienced significant stock fluctuations, currently priced at $13.53, down from a 52-week high of $22.50. The company has underperformed compared to the S&P 500 over the past year and three years, indicating ongoing challenges in the biotechnology sector.

Syndax Pharmaceuticals Experiences Evaluation Revision Amid Mixed Market Signals and Performance Trends

2025-10-13 15:36:26

Syndax Pharmaceuticals, Inc. has recently revised its evaluation amid market dynamics, with its stock priced at $16.06. The company has shown significant volatility over the past year, with a 52-week high of $22.50 and a low of $8.58, while demonstrating notable year-to-date returns compared to the S&P 500.

Is Syndax Pharmaceuticals, Inc. technically bullish or bearish?

2025-09-20 19:49:42

As of 8 September 2025, the technical trend for Syndax Pharmaceuticals, Inc. has changed from mildly bullish to mildly bearish. The weekly MACD and KST are bullish, while the monthly MACD and KST are bearish, indicating mixed signals across different time frames. The daily moving averages are bullish, but the Bollinger Bands and Dow Theory suggest a bearish stance on the monthly level. The stock has underperformed against the S&P 500 over the past week and month, with returns of -5.62% and -2.65% compared to the S&P's gains of 1.05% and 2.33%, respectively. Overall, the current technical stance is mildly bearish, reflecting weakness in the longer-term indicators....

Is Syndax Pharmaceuticals, Inc. overvalued or undervalued?

2025-09-20 18:24:30

As of 1 August 2024, the valuation grade for Syndax Pharmaceuticals, Inc. has moved from does not qualify to risky, indicating a shift towards a more cautious outlook. The company appears to be overvalued given its high Price to Book Value of 4.58 and negative EV to EBIT and EV to EBITDA ratios of -2.38, which suggest significant operational challenges. Additionally, the Return on Capital Employed (ROCE) and Return on Equity (ROE) are alarmingly low at -730.60% and -154.01%, respectively, further underscoring the company's financial difficulties. In comparison to its peers, Syndax's P/E ratio is not applicable due to its loss-making status, while Protagonist Therapeutics, Inc. is considered very expensive with a P/E of 67.1750, and Aurinia Pharmaceuticals, Inc. is fairly valued with a P/E of 20.8727. The stock has underperformed against the S&P 500 across multiple periods, with a 1-year return of -14.17% c...

View All News